Kiniksa Pharmaceuticals, Ltd.

Total Valuation

Kiniksa Pharmaceuticals, Ltd. carries a market capitalization of 3.60B, placing it among publicly traded companies globally. Its enterprise value stands at 3.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Kiniksa Pharmaceuticals, Ltd. currently has 76.69M shares outstanding.

Valuation Ratios

Kiniksa Pharmaceuticals, Ltd. trades at a trailing price-to-earnings ratio of 49.53. The price-to-sales ratio is 4.80, and the price-to-book ratio stands at -8.23.

Enterprise Valuation

On an enterprise value basis, Kiniksa Pharmaceuticals, Ltd. trades at an EV/EBITDA multiple of 33.30 and an EV/FCF ratio of 18.87. The EV/Sales ratio of 4.19 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 33.90 provides insight into valuation relative to core operating earnings.

Financial Position

Kiniksa Pharmaceuticals, Ltd. maintains a current ratio of 3.79, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Over the trailing twelve months, Kiniksa Pharmaceuticals, Ltd. has paid 32.93M in income taxes, reflecting an effective tax rate of 31.07.

Stock Price Statistics

Kiniksa Pharmaceuticals, Ltd.'s stock has gained approximately 64.3765% over the past 52 weeks. The 50-day moving average sits at 50.23, while the 200-day moving average is 42.94.

Income Statement

Over the trailing twelve months, Kiniksa Pharmaceuticals, Ltd. generated 754.05M in revenue and converted that into 73.06M in net income, yielding earnings per share of 0.91. EBITDA reached 94.89M, while operating income came in at 93.22M.

Balance Sheet

Kiniksa Pharmaceuticals, Ltd. holds 468.09M in cash and equivalents against 9.03M in total debt, resulting in a net debt position of -189.95M. Total book value stands at -439.52M, with working capital of 437.56M providing operational flexibility.

Cash Flow

Kiniksa Pharmaceuticals, Ltd. produced 165.86M in operating cash flow over the past twelve months. After subtracting -1.63M in capital expenditures, free cash flow totaled 164.23M - equivalent to 2.19 per share.

Margins

Kiniksa Pharmaceuticals, Ltd. operates with a gross margin of 54.65, reflecting its pricing power and cost economics. The operating margin of 12.36 and net profit margin of 9.69 provide insight into operational efficiency.

Dividends & Yields

Scores

Kiniksa Pharmaceuticals, Ltd. posts an Altman Z-Score of 11.09, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.